Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Stephens & Co. 啓動對catalyst pharmaceuticals的覆蓋，給出超配評級，宣佈目標價爲35美元。
Stephens & Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight rating and announces Price Target of $35.
Stephens & Co. 分析師蘇丹·洛根納桑對catalyst pharmaceuticals（納斯達克：CPRX）首次進行覆蓋，給予超配評級，並宣佈價格目標爲35美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間